995 results on '"Zlotta, Alexandre R."'
Search Results
102. EXPRESSION ANALYSIS OF LOW AND HIGH-GRADE HUMAN BLADDER CANCER TUMOUR SAMPLES AND BLADDER CANCER CELL LINES WITH RNA-SEQ IDENTIFIES A NEW GROUP OF ENHANCER RNAS WITH POTENTIAL REGULATORY FUNCTION: MP28-13
103. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial
104. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
105. Laparoscopic Partial Nephrectomy with “On-Demand” Clamping Reduces Warm Ischemia Time
106. How do I treat and follow my TUNA patients
107. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness
108. Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis
109. Trimodal therapy in muscle invasive bladder cancer management
110. Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches
111. Transurethral Needle Ablation of the Prostate
112. Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes
113. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma
114. Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men
115. INITIAL RESULTS OF MR GUIDED LASER FOCAL THERAPY FOR PROSTATE CANCER: 554
116. Comparison of laparoscopic radical prostatectomy techniques
117. Does patient age affect survival after radical cystectomy?
118. Hormone Therapy: Improving Therapy Decisions and Monitoring
119. Neoadjuvant and adjuvant hormone therapy for prostate cancer
120. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer
121. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome
122. Editorial Comment
123. Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer
124. Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records
125. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort
126. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study
127. LONG-TERM FOLLOW-UP OF T1 HIGH-GRADE BLADDER CANCER AFTER INTRAVESICAL BACILLE CALMETTE-GUÉRIN TREATMENT
128. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment
129. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†
130. A Prospective Randomized Controlled Trial of Irrigation “Bag Squeeze” to Manage Pain for Patients Undergoing Flexible Cystoscopy
131. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure
132. Novel use of an old compound? Urologist‐led Bacille Calmette–Guérin vaccine trials in the prevention of coronavirus disease 2019
133. Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-based, Diagnostic Study
134. Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer
135. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade
136. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
137. Salvage radical prostatectomy following focal therapy: functional and oncological outcomes
138. Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients
139. Optimal timing of radical cystectomy in T1 high-grade bladder cancer
140. Lynch Syndrome in Urologic Malignancies – What Does the Urologist Need to Know?
141. Nonprimary pT1 Nonmuscle Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin is Associated With Higher Risk of Progression Compared to Primary T1 Tumors
142. Pathological stage review is indicated in primary pT1 bladder cancer
143. The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma
144. Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer1
145. WHAT IS THE LONG TERM PROGNOSTIC VALUE OF PRO-APOPTOTIC, ANTI-APOPTOTIC, PROLIFERATION AND INVASIVENESS MOLECULAR MARKERS IN PATIENTS TREATED WITH BCG FOR HIGH RISK NON-INVASIVE BLADDER CANCER?: 1915
146. WHAT IS THE LONG TERM PROGNOSTIC VALUE OF PROAPOPTOTIC, ANTI-APOPTOTIC, PROLIFERATION AND INVASIVENESS MOLECULAR MARKERS IN PATIENTS TREATED WITH BCG FOR HIGH RISK NON-INVASIVE BLADDER CANCER?: 1915
147. Prostate cancer: a serious disease suitable for prevention
148. Quality of Life after Radical Prostatectomy: How to Preserve Potency?
149. Evaluation of Male Sexual Function in Patients with Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Treated with a Phytotherapeutic Agent (Permixon ®), Tamsulosin or Finasteride
150. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.